

## DAFTAR PUSTAKA

- Abdullah A, Qasim M, Shafiq M,*et al*, 2016. Molecular diagnosis and phylogenetic analysis of human papillomavirus type-16 from suspected patients in Pakistan. *Infectious Agents and Cancer J* 11: 1.
- Alix A, 1999. Predictive estimation of protein linear epitopes by using the program PEOPLE. *Vaccine J* 18: 311-4.
- Alfaro A, Juarez-Torres E, Medina-Martinez I,*et al*, 2016. Different association of human papillomavirus 16 variants with early and late presentation of cervical cancer. *PLoS ONE* 11: e0169315.
- Amador-Molina A, Hernandez-Valencia JF, Lamoyi E,*et al*, 2013. Role of innate immunity against human papillomavirus (HPV) infections and effect of adjuvants in promoting specific immune response. *Viruses* 5: 2624–42.
- Awua AK, Sackey ST, Osei SYD, Asmah RH, Wiredu EK. Prevalence of human papillomavirus genotypes among women in cervical cancer in Ghana. *Infect Agent Cancer*. 2016; 11(4).
- BarlowD, EdwardsM, ThorntonJ, 1986. Continuous and discontinuous protein antigenic determinant. *Nature J* 322: 747-8.
- Bin H, Ruifang W, Ruizhen L, *et al*, 2013. Detection of HPV L1 Capsid Protein and hTERC gene in screening of cervical cancer. *Iran J Basic Med Sci*. 2013 Jun; 16 (6): 797-802.
- Boyraz G, Basaran D, Salman MC, Ozgul N, Yuce K. Clinical and pathological characteristics related to parametrial involvement in clinical early stage cervical cancer. *Ginekologia Polska*. 2016;87(6): 417-21.
- Bramanuditya A, Santoso S, Muslihatun W N. Hubungan antara pernikahan usia muda dengan kejadian kanker serviks di RSUP DR. Sardjito Yogyakarta [tesis]. Politeknik Kesehatan Kementerian Kesehatan Yogyakarta. 2018.
- BurdEM, 2003. Human papillomavirus and cervical cancer. *Clinical Microbiology Reviews* 16: 1–17.
- BuckCB, Day PM, Trus BL, 2013. The papillomavirus major capsid protein L1. *Virology J* 445: 169-74.
- Buckley CH, Arends MJ, Wells M, 1998. Aetiology, pathogenesis, and pathology of cervical neoplasia. *J Clin Pathol* 51: 96-103.
- Caroline AJH, Boulet G, Renoux VM,*et al*, 2010. Mechanisms of cell entry by human papillomaviruses: an overview. *Virology Journal* 7:11

Castellsagué X, 2008. Natural history and epidemiology of HPV infection and cervical cancer. *Gynecologic oncology* J 110: S4–7.

Chabeda A, van Zyl AR, Rybicki EP, Hitzeroth II. Substitution of human papillomavirus type 16 L2 neutralizing epitope into L1 surface loops:the effect on Virus Like Particle assembly and immunogenicity. *Front Plant Sci.* 2019;10:779.

Chao A, Huang HJ, Lai CH, 2012. Human papillomavirus research on the prevention, diagnosis, and prognosis of cervical cancer in Taiwan. *Chang Gung Med J* 35: 97-308.

Chiesa IJ, Perez MS, Nunez GG, Pirola DA,*et al*, 2016. Genetic variability and phylogeny analysis of partial L1 gene of human papillomavirus variants in Buenos Aires, Argentina. *VirusDis* 27: 41-7.

Ciapponi A, Bardach A, Glujovsky D, Gibbons L, Picconi MA, 2011. Type-specific HPV prevalence in cervical cancer and high-grade lesions in Latin America and the Caribbean: systematic review and meta-analysis. *PLoS One* 6: e25493.

Cortes GE, Cerdá RM, Leal K, *et al*. 2003. Validating polymerase chain reaction for detecting HPV in cervical intraepithelial neoplasia. *Anal Quant Cytol Histol* 25(2): 115-8.

Coser J, Boeira TR, Fonseca AS, *et al*, 2011. Human papillomavirus detection and typing using a nested-PCR-RFLP assay. *Braz J Infect Dis* 15: 467-72.

Costa S, Venturolli S, Origoni M,*et al*, 2015. Performance of HPV DNA testing in the follow-up after treatment of high-grade cervical lesions, adenocarcinoma *in situ* (AIS) and microinvasive carcinoma. *Ecancermedicalscience* 9: 528.

Crum CP, BarberS,Roche JK, 1991. Pathobiology of papillomavirus-related cervical diseases: prospects for immunodiagnosis. *Clinical Microbiology Reviews*4: 270–85.

Damayanti. Faktor-faktor yang Berhubungan dengan Kejadian Kanker Serviks di RSUD Arifin Achmad Pekanbaru Tahun 2008-2010. *Jurnal Kesehatan Komunitas*, . 2013;2(2).

Dasgupta J, Bienkowska-Haba M, Ortega ME, *et al*, 2011. Structural basis of oligosaccharide receptor recognition by human papillomavirus. *The Journal of Biological Chemistry* 286:2617–24.

Deligeoroglou E, Giannouli A, Athanasopoulos N,*et al*, 2013. HPV infection: immunological aspects and their utility in future therapy. *Infectious Diseases in Obstetrics and Gynecology* J: 1-9.

de Boer MA, Peters LAW, Aziz MF,*et al*, 2004. Human papillomavirus type 16 E6, E7 and L1 variants in cervical cancer in Indonesia, Suriname and the Netherlands. *Gynecologic Oncology* 94: 488-94.

de Sanjose S, Quint WG, Alemany L, *et al*: Retrospective International Survey and HPV Time Trends Study Group: Human papillomavirus genotype attribution in invasive cervical

cancer: A retrospective cross-sectional worldwide study. Lancet Oncol. 11:1048–1056. 2010.

Departemen Kesehatan RI. Stop Kanker: 2013. 2015. Info-datin: 4.

Dias D, Doren J, Schlottmann S,*et al*, 2005. Optimization and validation of a multiple luminex assay to quantify antibodies to neutralizing epitopes on human papilomavirus 6, 11, 16, 18. Clinical and Diagnostic Laboratory Immunolog 12: 959–69.

Dwipoyo B. Kanker serviks dan vaksin HPV. Ind Jour of Cancer. 2007(3): 87-91.

Ebrahimi M, Seyyedtabaei SJ, Ranjbar MM, *et al*, 2019. Designing and modeling of multi-epitope proteins for diagnosis of *Toxocara canis* infection. International Journal of Peptide Research and Therapeutics. DOI: 10.1007/s10989-019-09940-1

Einstein MH, Schiller JT, Viscidi RP, *et al*. 2009. Clinician's guide to human papilomavirus immunology: knowns and unknowns. Lancet Infect Dis. 347-56.

El-Aliani A, El Alaoui MA, Chaoui I,*et al*, 2017. Naturally occurring capsid protein variants L1 of human papillomavirus genotype 16 in Morocco. Bioinformation 13: 241-8.

Eleje GU, *et al*. Palliative Intervention for Controlling Vaginal Bleeding in Avanced Cervical Cancer. Cochrane Systematic Review. 01 May 2015.

Egawa N, Egawa K, Griffin H, Doorbar J, 2015. Human papillomaviruses; epithelial tropisms, and the development of neoplasia. *Viruses*7: 3863-90.

Endo F, Tabata T, Sadato D, Kawamura M, Ando N, *et al*. (2017) Development of a simple and quick immunochromatography method for detection of anti-HPV-16/-18 antibodies. PLOS ONE 12(2): e0171314. <https://doi.org/10.1371/journal.pone.0171314>

Fadhilah FR, Sahiratmadja E, Safitri R, *et al*, 2015. Analisis filogenetik gen L1 human papillomavirus 16 pada penderita kanker serviks di Bandung. Majalah Kedokteran Bandung 47: 174-8.

Ferchichi MJ, Satouri L, Ghoul F, Mellouli MM, Derbel AM, Makni MK, Reziga H, *et al*. phylogeny and classification of human papillomavirus (HPV) 16 variants based in E6 and L1 genes in Tunisian Woman with cervical lesions. Asian Pac Jour of Canc Prev. 2017(19): 3361-6.

FerlayJ, Shin H, Bray F,*et al*, 2010. Estimates of worldwide burden of cancer in 2008: Globocan 2008. International Journal of Cancer127: 2893-917.

Fleiss, J. L. 1981. Statistical and methods for rates and proportions. 2<sup>nd</sup> ed. New York: John Wiley p. 38-46.

Flower DR, 2007. Immunoinformatics and the in silico prediction of Immunogenicity, 1st Ed. Totowa NJ: Humana.

Food and Drugs Administration. Gardasil 9. 2018. [cited December 6 2019]. Available from: <https://www.fda.gov/media/90064/download>.

Franco EL, Rohan TE, Villa LL. Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst. 1999;91:506-511.

Frati E, Bianchi S, Colzani D,*et al*, 2011. Genetic variability in the major capsid L1 protein of human papillomavirus type 16 (HPV-16) and 18 (HPV-18). Infection, Genetics and Evolution 11: 2119-24.

GantiK, Broniarczyk J, Manoubi W,*et al*,2015. The human papillomavirus E6 PDZ binding motif: From life cycle to malignancy. Viruses 7: 3530–51.

Gius D, Funk MC, Chuang EY,*et al*, 2007. Profiling microdissected epithelium and stroma to model genomic signatures for cervical carcinogenesis accommodating for covariates. Cancer Res 67: 7113–23.

Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. . 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492

Greenbaum J, Andersen PH, Blythe M,*et al*, 2007. Towards a consensus on datasets and evaluation metrics for developing B-cell epitope prediction tools. Journal of Molecular Recognition 20: 75-82.

Guliano AR, Sedjo RL, Roe DJ, Harri R, Baldwi S, Papenfuss MR, et al. clearance of oncogenic human papillomavirus (HPV) infection: effect of smoking (United States). Cancer Causes Control. 2003;13:839-46.

Gurgel AP, Chagas BS, Amaral CM, Nascimento KC, Leal LR, Neto JC, et al. prevalence of human papillomavirus variants and genetic diversity I the L1 gene and long control region of HPV16, HPV31, and HPV58 found in North East Brazil. Biomed Res Int. 2015;1-12.

Harjono, M. Kanker Serviks Displasia Dapat Disembuhkan. Medika Jurnal No 3 Tahun XXVIII. 2001.

Haryani S, Defrin D, Yenita Y. Prevalensi kanker serviks berdasarkan paritas di RSUP Dr. M. Djamil Padang periode Januari 2011 – Desember 2012. Jurnal Kesehatan Andalas,2016;5(3).

Hilfrich R. HPV L1 detection as a prognostic marker for management of HPV high risk positive abnormal pap smears. Germany: Cytoimmun Diagnostics GmbH Pirmasens. 2013: 93-116.

Hong Y, Fang Y, Zhao F, *et al*. 2014. High-risk HPV nucleic acid detection kit-the care HPV test-a new detection method for screening. Sci. Rep. 4, 4704; DOI:10.1038/srep04704.

Horvath C, Boulet G, Renoux VM,*et al*, 2010. Mechanisms of cell entry by human papillomaviruses:an overview. *Virology Journal* 7: 11.

Human Papillomavirus (HPV) and Cervical Cancer, 2015. WHO media centre fact sheet.

HuangB, Ruifang W, Ruizhen L,*et al*, 2013. Detention of HPV L1 capsid protein and hTERC gene in screening of cervical cancer. *Iranian Journal of Basic Medical Sciences* 16: 797–802.

JiangPYY, 2014. Human papillomavirus oncoproteins and apoptosis (review)." Experimental and Therapeutic Medicine 7: 3–7.

Karki *et al*, 2015. Defining mutation and polymorphism in the era of personal genomics. *BMC Medical Genomics* (2015) 8:37.

Khasbiyah. Beberapa Faktor Risiko Kanker Serviks Uteri (Studi Pada Penderita Kanker Serviks Uteri Di Rumah Sakit Dokter Kariadi Semarang Pada Bulan Agustus-September 2004).Tesis tidak diterbitkan. 2004. Diponegoro University

King AJ, Sonsma JA, Vriend HJ,*et al*, 2016. Genetic diversity in the major capsid L1 protein of HPV-16 and HPV-18 in the Netherlands. *PLoS ONE* 11: e0152782.

Klug, William S, *et al*. 2010. Concepts of genetics. 10<sup>th</sup> ed, Pearson, p600.

Kulmala SM, Syrjanen S, Shabalova I, *et al*. 2004. Human papillomavirus testing with the hybrid capture 2 assay and PCR as screening tool. *American Society for Microbiology* 42: 2470-5.

Larsen JEP, Lund O, Nielsen M, 2006. Improved method for predicting linear B-cell epitopes. *Immunome Research* 2: 1-7.

Lee SJ, Lee AW, Kang CS, Park JS, Park DC, Ki YE, *et al*. Clinopathological implications of Human Papilloma Virus (HPV) L1 capsid protein immunoreactivity in HPV16 Positive Cervical Cytology. *Int J Med Sci*. 2014;11(1): 80-6.

Liang TC, 1998. Epitopes. *Encyclopedia of Immunology*: 825-7.

Liu YQ, Xin He, Xu S,*et al*, 2015. Epidemiology and genotype distribution of high risk human papillomavirus in population of hospital opportunistic screening. *Int J Clin Exp Med* 8: 16007-14.

Lowy DR & Schiller JT. 2006. Prophylactic *Human Papilomavirus* Vaccine. *J Clin Invest* 116 (5): 1167-73.

Mariani L, Sandri MT, Preti M,*et al*, 2016. HPV-testing in follow-up of patients treated for CIN2+ lesions. *J Cancer* 7: 107-14.

Mendes D, Bains I, Vanni T, Jit M,2015. Systematic review of model-based cervical screening

evaluations. *BMC Cancer* 15: 334.

Mohabatkar H. Prediction of epitopes and structural properties of Iranian HPV-16 E6 by bioinformatics methods. *Asian Pac J Cancer Prev.* 2007;8(4):602-606.

Moody CA, Laimins LA, 2010. Human papillomavirus oncoproteins: pathways to transformation. *Nature Reviews Cancer* 10: 550–60.

Morbidity and Mortality Weekly Report (MMWR), 2014. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Mukonyora M, 2015. A review of important discontinuous B-cell epitope prediction tools. *Journal of Clinical & Cellular Immunology* 6: 1-5.

Namvar A, Bolhassani A, Javadi G, Moormohammadi Z. In silico/in vivo analisis of high risk papillomavirus L1 dan L1 conserved sequences for development of cross-subtype prophylactic vaccine. *Scientific Report*. 2019(9): 15225.

Nugraha J. Pemetaan epitop dan aplikasi klinisnya. *Clin Path And Med Lab.* 2011;17(3): 166-70.

Nuranna L, Donny NB, Purwoto G, Winarto H, Utami TW, Anggraeni TD, et al. Prevalence, age distribution, and risk factors of visual inspection with acetic acidpositive form 2007to 2011 in Jakarta. *Jour of Cancer Prev.* 2017;22(2): 103-7.

Nuswantara S, Prana TK, Wulandari D,*et al*, 2010. Conservation of major L1 and variability of minor L2 capsid late protein genes in human papillomavirus of Indonesia variants. *Annales Bogoriensis* 14: 1-8.

OdoricoM, Pellequer J, 2003. BEPIPOPE: predicting the location of continuous epitopes and patterns in proteins. *Journal of Mollecular Recognition* 16: 20-2.

Pande S, Jain N, Prusty BK, Bhambhani S, Gupta S, Sharma R, et al. Human papillomavirus type 16 variant analysis of E6, E7, and L1 genes and long control region in biopsy samples from cervical cancer patients in North India. *Jour of Clin Micro.* 2008: 1060-6.

Perez C, Suarez E, Unger ER, Palefsky JM, Panicker G, Ortiz AP. Seroprevalence of human papillomavirus type 6,11,16,18, by anatomic site of HPV infection, in women aged 16-64 years living in the metropolitan area of San Juan, Puerto Rico. *P R Health Sci J.* 2018;37(1):26-31

Pinto AP, Degen M, Villa L, Cibas E, 2012. Imunomarkers in gynecologic cytology: the search for the ideal biomoleculer papanicolaou test. *Acta Cytologica* 56:109–21.

Pradita A, Sahiratmadja E, Suhandono S, Susanto H. Sekuens gen protein kapsid mayor L1 *Human Papilomavirus* 16 dari isolat klinik asal Bandung. Bandung: MKB; 46(3). 2014.

Purnama ER, Kharisma VD. Epitope mapping of capsid protein L1 from Human Papillomavirus to development cervical cancer vaccine through computational study. J. Phys. Conf. Ser. 2018; **1108** 012096.

Raff AB, Woodham A, Raff L, Skeate JG, Yan L, SilvaDMD, 2013. The evolving field of human papilomavirus receptor research: a review of binding and entry. [Journal of Virology](#)87.

Riemer AB, Keskin DB, Zhang G, Handley M, et al, 2010. A conserved E7-derived cytotoxic T Lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers. Journal of Biological Chemistry 285: 29608-22.

Robbins, Li Y, Porras C,et al, 2014. Glutathione s-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus.BMC Infectious Diseases14: 120.

Sabalza M, Barber CA, Abrams WR, et al, 2017. Zika virus specific diafnostic epitope discovery. Journal of Visualized Experiments 2017; (130): 56784. DOI: 10.3791/56784

SahaS, BhasinM, Raghava GP, 2005. Bcipep: a database of B-cell epitopes. BMC Genomics6: 79.

Savira M, Maryanti E, Donel, 2016. Analisis korelasi *infeksi human papillomavirus* dengan manifestasi klinis keganasan serviks.Laporan penelitian Hibah Bersaing.

Schellekens MC, Dijkman A, Aziz MF, et al, 2004. Prevalence of single and multiple HPV types in cervical carcinomas in Jakarta, Indonesia. Gynecol Oncol 93: 49-53.

Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, et al. Baseline cytology human papillomavirus testing and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003;95:46---52

Setyarini, E. Faktor- Faktor Yang Berhubungan Dengan Kejadian Kanker Leher Rahim Di RSUD Dr. Moewardi Surakarta. Skripsi tidak diterbitkan. Universitas Muhammadiyah Surakarta. 2009.

SicheroL, Villa LL, 2006.Epidemiological and functional implication of molecular variants of human papillomavirus. Brazillian Journal of Medical and Biological Research39: 707-17.

Sirait CM. Karakteriasasi Human papilloma virus (HPV) tipe 16 dan 18 secara Random Amplified Polymorphic DNA (RAPD) [tesis]. Fakultas Kedokteran Universitas Andalas. 2018.

Sollner J, Mayer B, 2006. Machine learning approaches for prediction of linear B-cell epitopes on proteins. Journal of Mollecular Recognition19: 200–8.

Song D, Li H, Li H, Dai J, 2015. Effect of human papillomavirus infection on the immune system and its role in the course of cervical cancer (review). Oncology Letters 10: 600-6.

- Sopiyudin, 2009. Penelitian diagnostic: dasar-dasar teoritis dan aplikasi dengan program SPSS dan Stata. Jakarta: Salemba Medika.
- Stanley M, 2008. Immunobiology of HPV and HPV vaccines. *Gynecologic Oncology* 109:S15-21.
- Tate P, 2009. Seeley's Principles of Anatomy & Physiology. McGraw-Hill Publishing.
- Teimoori A, Soelemanjahi H, Fotouhi F, Meshkat Z, 2008. Isolation and cloning of L1 HPV 16 gene from Iranian isolate. *Saudi Medical Journal* 29: 1105-8.
- Tempfer CB, Tischhoff I, Dogan A, et al. Neuroendocrine carcinoma of the cervix: a systematic review of the literature. *BMC Cancer*. 2018;18(1):530. Published 2018 May 4. doi:10.1186/s12885-018-4447-x
- Téllez L, Michelli E, Mendoza JA, et al 2015. Persistent infection with high-risk human papilloma viruses: cohort study, Mérida, Venezuela. *Ecancermedicalscience* 9: 579.
- Van Doorslaer K, Burk RD, 2010. Evolution of human papillomavirus carcinogenicity. *Advances in Virus Research* 77: 41–62.
- Venuti F, Paolini L, Nasir A, Corteggio S, Roperto MS, Campo G, 2011. Borzacchiello papillomavirus E5: the smallest oncoprotein with many functions. *Mol Cancer* 10.
- Vet JNI, de Boer MA, van de Akker B, et al, 2008. Prevalence of human papillomavirus in Indonesia: a population-based study in three regions. *Br J Cancer* 99: 214-18.
- Villiers EMD, Fauquet C, Broker TR, Bernard HU, Hausen HZ, 2004. Classification of papillomaviruses. *Journal of Virology* 324: 17-27.
- Volpini LPB, Boldrini NATD, de Freitas LB, Miranda AE, Spano LC. The high prevalence of HPV and HPV 16 European variants in cervical and anal samples of HIV seropositive women with normal PAP test result. *Plos ONE*. 2017;12(4).
- Wahyuningsih, Tri., Mulyani, Erry Yudhya. Faktor Resiko Terjadinya Lesi Prakanker Serviks Melalui Deteksi Dini Dengan Metode IVA (Inspeksi Visual Dengan Asam Asetat). *Forum Ilmiah*. 2014;11(2).
- Wallace NA, Galloway DA. 2014. Manipulation of cellular DNA damage repair machinery facilitates propagation of human papillomaviruses. *Cancer Biol*: 30–42.
- Wang A, Li N, Zhou N, Chen Y, Juang M, Qi Y, et al. Mapping the B cell epitopes within the major capsid protein L1 of human papillomavirus type 16. *Biomac*. 2018.
- Wang Y, Shang Q, Xu W, et al, 2014. Characterization of two new monoclonal antibodies against human papillomavirus type 16 L1 protein. *Diagnosyic Pathology* 9: 101.

Wang Y, Wan G, Zhang D, Yin H, Wang M. Identification of novel B cell epitopes within *Toxoplasma gondii* GRA1. Experimental Parasitology. 2013; 1-22.

Wang JW, Roden RBS, 2013. L2, the minor capsid protein of papillomavirus. Virology Journal 445: 175-186.

Weber CA, Mehta PJ, Ardito M, Moise L, Martin B, De Groot AS, 2009. T cell epitope: Friend or Foe? Immunogenicity of biologics in context. Adv Drug Deliv Rev: 1-12.

World Health Organisation. Human Papillomavirus (HPV) Factsheet. WHO. [Online] 3 September 2010. [Cited: 19 May 2015.] <http://www.who.int/immunization/topics/hpv/en/>.

Xavier C, 2008. Natural history and epidemiology of HPV infection and cervical cancer. Gynecologic Oncology 110: S4-S7.

Yuan CH, Filippova M, Duerksen-Hughes P, 2012. Modulation of apoptotic pathways by human papillomaviruses (HPV): mechanisms and implications for therapy. Viruses 4: 3831–50.

Zajonc DM, 2003. Antibody recognition of immunodominant vaccinia virus envelope proteins. In (Harris JR, Marles-Wright J, eds) Macromolecular protein complexes structure and function. Switzerland: Springer International Publishing, pp 119.

Zhang Q *et al*, 2016. Epidemiological investigation and risk factors for cervical lesions: cervical cancer screening among women in rural areas of Henan Province China. Med Sci Monit 2016; 22: 1858-1865.

Zhao Q, Modis Y, High K, *et al*, 2012. Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity. Virology Journal 9: 52.

Zuraedah E. Faktor-faktor resiko kanker leher rahim jenis karsinoma sel skuamosa di RSUPN dr. Cipto Mangunkusummo Jakarta. FKM UI. 2001.